Shichijo Shigeki, Azuma Kouichi, Komatsu Nobukazu, Ito Masaaki, Maeda Yoshiaki, Ishihara Yuki, Itoh Kyogo
Department of Immunology, Kurume University School of Medicine, Research Center of Innovative Cancer Therapy of the 21st Century COE Program for Medical Science, Kurume University, Kurume, Fukuoka, Japan.
Clin Cancer Res. 2004 Sep 1;10(17):5828-36. doi: 10.1158/1078-0432.CCR-04-0350.
The purpose of this work was to provide a scientific basis for specific immunotherapy of colon cancer.
This study focused on identification of colon tumor-associated antigens and HLA-A2-restricted and tumor-reactive cytotoxic T lymphocytes (CTLs) generated from tumor-infiltrating lymphocytes of a colon cancer patient. A gene expression cloning method was used to identify genes coding for tumor antigens. Fifty-six peptides with HLA-A2-binding motifs encoded by these proteins were examined for their ability to induce HLA-A2-restricted and tumor-reactive CTLs.
We identified the following three genes coding for proliferation-related proteins: thymidylate synthase (TYMS), which is involved in chemoresistance (5-fluorouracil); 5'-aminoimidazole-4-carboxamide-1-beta-d-ribonucleotide transfolmylase/inosinicase (AICRT/I); and phosphoglycerate kinase 1 (PKG1), which was secreted by tumor cells and involved in the angiogenic process. TYMS was preferentially expressed in tumor cells, whereas AICRT/I and PKG1 were equally expressed in both cancer cells and normal tissues at the mRNA level. Among 56 peptides with HLA-A2-binding motifs encoded by these proteins, 8 peptides were recognized by the CTLs, and 5 of 8 peptides were also recognized by the CTL precursors without ex vivo activation in the peripheral blood of colon cancer patients. Furthermore, four of them (one each from TYMS and PKG1 and two from AICRT/1) possessed the ability to induce HLA-A2-restricted and peptide-specific CTLs cytotoxic to colon tumor cells in peripheral blood mononuclear cells of colon cancer patients.
TYMS and PGK1, as well as their epitope peptides, might be appropriate target molecules for specific immunotherapy of HLA-A2(+) colon cancer patients because of the positive role of TYMS and PGK1 in chemoresistance (5-fluorouracil) and angiogenesis of tumor cells, respectively.
本研究旨在为结肠癌的特异性免疫治疗提供科学依据。
本研究聚焦于结肠癌肿瘤相关抗原的鉴定,以及从一名结肠癌患者的肿瘤浸润淋巴细胞中产生的HLA - A2限制性且具有肿瘤反应性的细胞毒性T淋巴细胞(CTL)。采用基因表达克隆方法来鉴定编码肿瘤抗原的基因。对由这些蛋白质编码的具有HLA - A2结合基序的56种肽进行检测,以评估它们诱导HLA - A2限制性且具有肿瘤反应性的CTL的能力。
我们鉴定出以下三个编码增殖相关蛋白的基因:胸苷酸合成酶(TYMS),其与化疗耐药性(5 - 氟尿嘧啶)有关;5'-氨基咪唑-4 - 甲酰胺-1 - β - D - 核糖核苷酸转甲酰酶/肌苷酸酶(AICRT/I);以及磷酸甘油酸激酶1(PKG1),它由肿瘤细胞分泌并参与血管生成过程。TYMS在肿瘤细胞中优先表达,而AICRT/I和PKG1在mRNA水平上在癌细胞和正常组织中均有同等程度的表达。在由这些蛋白质编码的具有HLA - A2结合基序的56种肽中,有8种肽被CTL识别,并且在结肠癌患者外周血中,8种肽中的5种在未经体外激活的CTL前体细胞中也能被识别。此外,其中4种肽(TYMS和PKG1各1种,AICRT/1 2种)具有在结肠癌患者外周血单个核细胞中诱导HLA - A2限制性且对结肠肿瘤细胞具有细胞毒性的肽特异性CTL的能力。
TYMS和PGK1及其表位肽可能是HLA - A2(+)结肠癌患者特异性免疫治疗的合适靶分子,因为TYMS和PGK1分别在肿瘤细胞的化疗耐药性(5 - 氟尿嘧啶)和血管生成中发挥了积极作用。